Browse the corpus

Epidermolytic hyperkeratosis, also referred to as "bullous ichthyosiform erythroderma," is a rare autosomal dominant disorder of cornification caused by mutations in keratins 1 and 10. The condition is characterized by erythroderma and blistering at birth, with subsequent development of hyperkeratosis. Epidermolytic hyperkeratosis typically presents at birth or early infancy with widespread blistering, skin fragility, and scaling, especially in areas often exposed to friction, such as the palms, soles, and joints. Blistering may decrease over time, but hyperkeratosis, or thickened, scaly skin, often persists and can worsen with age. Patients may experience recurrent infections in affected areas due to skin breakdown and fragility. Diagnosis of epidermolytic hyperkeratosis requires clinical examination, genetic testing, and, sometimes, a skin biopsy to confirm characteristic keratin mutations. Management includes topical keratolytics, moisturizers, and retinoids to reduce scaling, along with infection treatment or prevention measures. Epidermolytic hyperkeratosis has no cure. Symptoms may be managed effectively, though the condition may cause psychosocial difficulties in growing individuals. This activity for healthcare professionals is designed to enhance learners' competence in evaluating and managing epidermolytic hyperkeratosis. Trainees will gain a deeper understanding of the condition's etiology, pathophysiology, presentation, and recommended diagnostic and therapeutic practices. Greater proficiency will equip clinicians to collaborate within an interprofessional team caring for patients with this condition. Objectives: Identify the signs and symptoms suggestive of epidermolytic hyperkeratosis. Apply clinically guided diagnostic strategies for epidermolytic hyperkeratosis. Implement personalized, evidence-based management approaches for epidermolytic hyperkeratosis. Collaborate with the interprofessional team to educate, treat, and monitor patients with epidermolytic hyperkeratosis to improve overall health outcomes. Access free multiple choice questions on this topic.

Epidermolytic hyperkeratosis is a rare autosomal dominant pathology of cornification caused by mutations in keratins 1 and 10. The condition was originally termed "bullous congenital ichthyosiform erythroderma" owing to the hallmark features of erythroderma, blistering, and skin denudation present at birth, with subsequent development of marked hyperkeratosis. Symptoms occur with or without palmoplantar keratoderma. Epidermolytic hyperkeratosis may be distinguished from other forms of congenital ichthyosis by its characteristic histopathologic features. The condition has been reclassified in recent literature as a distinct pathologic entity referred to as "epidermolytic ichthyosis."[1][2][3]

Epidermolytic hyperkeratosis is primarily the result of point or missense mutations in the genes encoding keratins 1 (KRT1) and 10 (KRT10).[4][5][6] Most cases are transmitted through an autosomal dominant pattern of inheritance. A severe form of epidermolytic hyperkeratosis exists in 3 consanguineous pedigrees due to autosomal recessive loss-of-function mutations in keratin 10.[7][8] Sporadic mutations occur in up to 50% of cases.[9] Keratin 1 mutations have been associated with epidermolytic hyperkeratosis with severe palmoplantar keratoderma, while keratin 10 mutations cause a phenotype lacking palmoplantar keratoderma.[10] The offspring of parents with epidermal nevi may have generalized epidermolytic hyperkeratosis due to genetic mosaicism. The mosaic form of epidermolytic hyperkeratosis, variably labeled "ichthyosis hystrix" or "linear epidermolytic hyperkeratosis," is caused by postzygotic mutations in keratins 1 and 10 during embryogenesis. Mutations involving gonadal cells may result in transmission to offspring, resulting in phenotypic epidermolytic hyperkeratosis.[11] Currently, epidermolytic hyperkeratosis is the only known human keratin disease to exhibit genetic mosaicism.

Epidermolytic hyperkeratosis results from mutations that disrupt the integrity of the epidermal keratin network. Keratin proteins constitute the principal structural components required for epidermal stability and differentiation.[13] The epidermis protects against environmental stressors through an extensive cytoskeletal framework composed of keratin filaments. Genes encoding keratins 5 and 14 are expressed within the basal keratinocytes, whereas suprabasal keratinocytes undergoing terminal differentiation express keratins 1 and 10, which assemble into filaments thicker than the tonofilament bundles of basal cells. These thicker filament bundles enhance the mechanical resilience and stability of the epidermis.[14][15] Mutations associated with epidermolytic hyperkeratosis localize to the highly conserved α-helical rod domains of keratins 1 and 10. Alterations within helix boundary sequence motifs disrupt helix initiation and termination, resulting in defective filament assembly, tonofilament aggregation, and generally more severe clinical phenotypes. The structurally compromised epidermis becomes susceptible to cytolysis and blister formation, leading to impaired barrier function with consequent transepidermal water loss and increased susceptibility to bacterial colonization. The accompanying hyperkeratosis reflects basal cell hyperproliferation and reduced desquamation. The thickened epidermis of the palms and soles exhibits molecular expression patterns distinct from those of other cutaneous regions. Type I keratin 9 is expressed exclusively in these areas, and pathogenic variants in the corresponding gene result in region-specific keratoderma.[16] Many heritable hyperkeratotic disorders demonstrate an inflammatory component characterized by the upregulation of proinflammatory cytokines. Pathways involving T helper 17 (Th17) cells have been implicated in mediating excessive inflammatory responses.[17]

The thickened epidermis of the palms and soles exhibits molecular expression patterns distinct from those of other cutaneous regions. Type I keratin 9 is expressed exclusively in these areas, and pathogenic variants in the corresponding gene result in region-specific keratoderma.[16] Many heritable hyperkeratotic disorders demonstrate an inflammatory component characterized by the upregulation of proinflammatory cytokines. Pathways involving T helper 17 (Th17) cells have been implicated in mediating excessive inflammatory responses.[17] Electron microscopy studies by Chipev et al identified a leucine-to-proline point mutation within the H1 subdomain of keratin 1, producing marked disruption in filament structure and organization. Snyder et al subsequently described an arginine-to-histidine substitution in the amino-terminal α-helical rod domain of keratin 10 and a tyrosine-to-cysteine mutation in the carboxy-terminal domain of keratin 1.[18] Severe phenotypes of epidermolytic hyperkeratosis have been associated with specific genetic alterations, including deletion of exon 6 in the KRT1 gene and missense mutations in KRT10 (c.475T>C, p.Ser159Pro) and KRT1 (c.562A>C, p.Asn188His).[19]

Epidermolytic hyperkeratosis may be distinguished from other congenital ichthyoses by its characteristic histopathologic profile, which includes dense orthohyperkeratosis, hypergranulosis, coarse keratohyaline granules, and cytolysis within the suprabasal and granular layers. Keratinocytes demonstrate marked intracellular vacuolar degeneration and dense clumps of keratin intermediate filaments. Varying degrees of dyskeratosis and a mild perivascular lymphohistiocytic infiltrate also occur. Electron microscopy shows clumped keratin intermediate filaments at the suprabasal layer, and immunohistochemistry shows defects in keratin 1 or 10. Patients with the mosaic form of epidermolytic hyperkeratosis exhibit focal areas of involvement with skip areas of normal epidermis.

Epidermolytic hyperkeratosis presents at birth with generalized erythroderma. Skin fragility causes blisters, peeling or exfoliation, erosions, and widespread areas of denuded skin, even with minor trauma (see Image. Skin Fragility in Epidermolytic Hyperkeratosis). The erythema and blistering decrease after several months, and marked hyperkeratosis develops. Skin fragility occasionally persists, and patients periodically shed large plates of the superficial epidermis. Hyperkeratosis characteristically exhibits a “corrugated cardboard” appearance over flexural regions and a “cobblestone” pattern over joint extensor surfaces (see Image. Hyperkeratosis in Epidermolytic Hyperkeratosis). Severe scalp and neck involvement occurs occasionally, leading to the encasement of hair shafts and alopecia. Bacterial colonization of macerated scales produces a characteristic malodor often described as resembling sulfur or rotten eggs. Associated manifestations include xerosis, pruritus, painful fissuring, anhidrosis, and restricted joint mobility. Researchers have identified several different phenotypes of epidermolytic hyperkeratosis. DiGiovanna and Bale classified the condition into 2 main clinical categories in 1994 based on the presence or absence of palmoplantar keratoderma.[20] Each clinical category has 3 subtypes with varying degrees of erythroderma, blistering, scaling (in the nonpalmoplantar type), and truncal involvement (in the palmoplantar type). Palmoplantar disease may result in digital contractures and consequent functional impairment. The mosaic variant of epidermolytic hyperkeratosis presents with unilateral or bilateral streaks of hyperkeratosis following Blaschko lines. Cases with extensive involvement and hyperkeratotic projections resembling spines are termed "ichthyosis hystrix."

Diagnosis relies on the integration of clinical evaluation, histopathologic examination, and laboratory assessment. Genetic mutation analysis targeting keratin gene defects through multigene panel testing is the current gold standard and is applicable for prenatal screening. Prenatal diagnosis may be established through chorionic villus sampling, amniocentesis, or fetoscopic fetal skin biopsy, although these methods are limited by low sensitivity and genetic heterogeneity. Emerging spectroscopic and optical modalities, including Raman spectroscopy and optical coherence tomography—techniques currently applied in the in vivo detection of nonmelanoma skin cancers—show potential utility in the diagnosis of epidermolytic hyperkeratosis.

Treatment is primarily symptomatic and varies according to patient age and clinical presentation. Infants presenting with dehydration, electrolyte imbalance, or cutaneous superinfection require intensive care management. Broad-spectrum intravenous antibiotics are indicated in the presence of sepsis. Topical emollients and protective dressings should be applied to promote healing of denuded skin and maintain barrier integrity. The principal therapeutic objective in children and adults is the reduction of hyperkeratosis. Topical emollients and keratolytic formulations containing glycerin, lactic acid, urea, or α-hydroxy acids have demonstrated efficacy in softening and reducing hyperkeratotic plaques but may cause local irritation, manifesting as burning or stinging. Application of high-concentration salicylic acid preparations over extensive body surface areas should be avoided to prevent systemic salicylate toxicity. Topical retinoids, N-acetylcysteine, liarozole, and calcipotriol have demonstrated efficacy in modulating corneocyte differentiation and reducing epidermal hyperproliferation, although these agents may induce local irritation. In severe forms of epidermolytic hyperkeratosis, oral retinoids can markedly improve hyperkeratosis and reduce the frequency of secondary infection but may paradoxically increase skin fragility and exacerbate blister formation. Initiation with low doses followed by gradual titration under close clinical monitoring is recommended.[21] Patients harboring keratin 10 mutations generally exhibit better therapeutic response to topical or systemic retinoids than those possessing keratin 1 mutations. Adjunctive measures, such as the use of antibacterial cleansers, chlorhexidine preparations, or dilute sodium hypochlorite baths, help reduce bacterial colonization. Topical or systemic antibiotic therapy is indicated when overt bacterial infection develops.

The differential diagnosis of epidermolytic hyperkeratosis includes other causes of erythroderma, bulla and blister formation, or exfoliation in childhood. These conditions include the following: Other congenital ichthyoses: Superficial epidermolytic ichthyosis Lamellar ichthyosis Congenital ichthyosiform erythroderma Vesiculobullous and erosive disorders in childhood: Epidermolysis bullosa Staphylococcal scalded skin syndrome Bullous impetigo Herpes simplex Congenital erosive and vesicular dermatosis Autoimmune blistering diseases Genodermatoses: Sjogren-Larsson syndrome Neutral lipid storage disease Trichothiodystrophy Netherton syndrome Steroid sulfatase deficiency Peeling skin syndromes Conradi-Hunermann-Happle syndrome Syndrome of congenital hemidysplasia with ichthyosiform dermatosis and limb defects (CHILD) Keratitis-ichthyosis-deafness (KID) syndrome A good clinical history and judicious diagnostic testing, including genetic studies, can distinguish epidermolytic hyperkeratosis from these conditions and guide management appropriately.

Epidermolytic hyperkeratosis has variable severity. Neonates with this disorder are at increased risk of sepsis, dehydration, and death. However, mortality rate data for this condition are lacking due to its rarity. For individuals who survive the neonatal period, episodes of blistering and skin infections occur intermittently throughout life. Consequently, patients often have significant disfigurement and pungent body odors, causing severe psychological and social distress.

Neonates born with epidermolytic hyperkeratosis are at higher risk of dehydration, electrolyte imbalances, and sepsis due to increased transepidermal water loss and ineffective skin barrier function. These complications are fatal without proper treatment. Severe palmoplantar involvement may also lead to digital contractures, which can impair joint mobility, gait, and posture.

Individuals with epidermolytic hyperkeratosis have increased skin fragility throughout life. Therefore, patients must be educated about ways to minimize mechanical trauma to the skin. Protective measures include wearing loose-fitting, comfortable clothes and well-fitting shoes.

Therapeutic approaches for hyperkeratosis continue to evolve, with pharmacologic research increasingly focused on agents that target specific genetic mutations through monoclonal antibody technology.[22] Advances in genetic testing, combined with the development of gene-based therapies, hold promise for expanding treatment options across a range of heritable hyperkeratotic disorders.[23] Recent studies have identified a subset of linear epidermal nevi demonstrating histologic features of epidermolytic hyperkeratosis, supporting the potential transmissibility of pathogenic keratin mutations to offspring. The probability of detecting such histopathologic abnormalities increases when multiple nevi are present, warranting consideration of genetic evaluation in affected individuals.[24]

Epidermolytic hyperkeratosis usually presents soon after birth. This condition has no cure, and the disorder is progressive. Treatment is primarily symptomatic and depends on the patient’s age and presentation. Interprofessional management should involve the family doctor, pediatrician, dermatologist, nurse practitioner, and physician assistant. Infants should be monitored in the intensive care setting to manage dehydration, electrolyte imbalance, and cutaneous superinfection. Sepsis should be treated with broad-spectrum intravenous antibiotics, which should have the pharmacist's input regarding coverage, dosing, and drug interaction monitoring. The nurse should educate the caregiver or parent about the use of topical emollients and protective padding for skin protection and healing of denuded areas, which should also have pharmacy input. Since patients have fragile skin, the nurse practitioner should also provide counseling on ways to minimize mechanical skin trauma, which may be achieved by wearing loose-fitting, comfortable clothes and well-fitting shoes. Due to the considerable psychosocial morbidity associated with the long-term sequelae of epidermolytic hyperkeratosis, coordinating care with an interprofessional team, including intensivists, infectious disease specialists, mental health nurses, and psychiatrists, is essential. Delays in diagnosis and management can produce adverse outcomes and, possibly, death. Collaboration and effective communication among all members of the healthcare team are crucial for achieving positive patient outcomes.